Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 3/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 5/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.35 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 2/20 | 0.35 |
| ▸ | PIM1 | P11309 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2999160 | 0.91 | CSF1R (0.36) | CSF1RPRKCQMAP4K1CNR2 | |
| SCHEMBL3013772 | 0.89 | PTGDR2 (0.40) | CSF1RCARM1MAOBHTR6MAPK1 | |
| SCHEMBL14905707 | 0.87 | TBK1 (0.43) | CSF1RCARM1MAOBHTR6MAPK1 | |
| SCHEMBL2999167 | 0.87 | CSF1R (0.49) | CSF1RLRRK2CNR2 | |
| SCHEMBL3011431 | 0.86 | CARM1 (0.42) | CSF1RCARM1MAPK1CCNA2CDK2 | |
| SCHEMBL3001997 | 0.86 | CARM1 (0.38) | CSF1RCARM1MAOBHTR6MAPK1 | |
| SCHEMBL3009007 | 0.85 | CSF1R (0.51) | CSF1RMAOBHTR6MAPK1CNR2 | |
| SCHEMBL3009677 | 0.84 | CARM1 (0.35) | CSF1RCARM1MAOBHTR6MAPK1 | |
| SCHEMBL3005318 | 0.83 | CHRM3 (0.42) | CSF1RMAPK1CNR2 | |
| SCHEMBL3007500 | 0.83 | CSF1R (0.44) | CSF1RMAPK1CCNA2CDK2MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213583-A1 | ANTIVIRAL PHARMACEUTICAL COMPOSITION AND USE THEREOF | MITOIMMUNE THERAPEUTICS INC. (KR) | 2025-07-03 | — | — | US | claimed |
| US-20250082646-A1 | OVARIAN ANTI-AGING PHARMACEUTICAL COMPOSITION AND USE THEREOF | MITOIMMUNE THERAPEUTICS INC. (KR) | 2025-03-13 | — | — | US | claimed |
| EP-4470541-A1 | OVARIAN ANTI-AGING PHARMACEUTICAL COMPOSITION AND USE THEREOF | MitoImmune Therapeutics Inc. (KR) | 2024-12-04 | — | — | EP | claimed |
| US-20240374646-A1 | COMPOSITION FOR INHIBITING INFLAMMATION OR AGING OF STEM CELLS, AND METHOD FOR INHIBITING INFLAMMATION OR AGING BY USING SAME | MITOIMMUNE THERAPEUTICS INC. (KR) | 2024-11-14 | — | — | US | claimed |
| WO-2024191106-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF EPILEPSY | 주식회사 미토이뮨테라퓨틱스 | 2024-09-19 | — | — | WO | claimed |
| CN-118647383-A | Anti-ovarian aging pharmaceutical composition and application thereof | 水疗免疫疗法有限公司 | 2024-09-13 | — | — | CN | claimed |
| US-20240269145-A1 | USE OF INDOLE COMPOUND AS INHIBITORS OF FERROPTOSIS | MITOIMMUNE THERAPEUTICS INC. (KR) | 2024-08-15 | — | — | US | claimed |
| EP-4382106-A1 | COMPOSITION FOR INHIBITING INFLAMMATION OR AGING OF STEM CELLS, AND METHOD FOR INHIBITING INFLAMMATION OR AGING BY USING SAME | MitoImmune Therapeutics Inc. (KR) | 2024-06-12 | — | — | EP | claimed |
| WO-2023182840-A1 | ANTIVIRAL PHARMACEUTICAL COMPOSITION AND USE THEREOF | 주식회사 미토이뮨테라퓨틱스 | 2023-09-28 | — | — | WO | claimed |
| WO-2023146341-A1 | OVARIAN ANTI-AGING PHARMACEUTICAL COMPOSITION AND USE THEREOF | 주식회사 미토이뮨테라퓨틱스 | 2023-08-03 | — | — | WO | claimed |
| WO-2022220517-A1 | COMPOSITION FOR INHIBITING INFLAMMATION OR AGING OF STEM CELLS, AND METHOD FOR INHIBITING INFLAMMATION OR AGING BY USING SAME | 주식회사 미토이뮨테라퓨틱스 | 2022-10-20 | — | — | WO | claimed |
| EP-2178870-B1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG CHEMICAL LTD (KR) | 2018-09-19 | — | — | EP | claimed |
| US-20150038500-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING OPHTHALMIC DISORDERS | CATHOLIC UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2015-02-05 | — | — | US | claimed |
| US-8436038-B2 | Indole and indazole compounds as an inhibitor of cellular necrosis | LG LIFE SCIENCES LTD. (KR) | 2013-05-07 | — | — | US | claimed |
| US-20100197673-A1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD (KR) | 2010-08-05 | — | — | US | claimed |
| EP-2178870-A1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG Life Sciences Ltd. (KR) | 2010-04-28 | — | — | EP | claimed |
| WO-2009025478-A1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2009-02-26 | — | — | WO | claimed |
| US-20250213583-A1 | ANTIVIRAL PHARMACEUTICAL COMPOSITION AND USE THEREOF | MITOIMMUNE THERAPEUTICS INC. (KR) | 2025-07-03 | — | — | US | disclosed |
| EP-2178870-A1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG Life Sciences Ltd. (KR) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009025478-A1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374646-A1 | COMPOSITION FOR INHIBITING INFLAMMATION OR AGING OF STEM CELLS, AND METHOD FOR INHIBITING INFLAMMATION OR AGING BY USING SAME | TFAM, FIS1, AIFM1 | CSF1R 1534/4885CARM1 2779/4885PIK3CA 4135/4885 |
| US-20250082646-A1 | OVARIAN ANTI-AGING PHARMACEUTICAL COMPOSITION AND USE THEREOF | CYP19A1, NR5A1, CYP11A1 | CSF1R 4503/4885CARM1 2905/4885PIK3CA 2194/4885 |
| US-20250213583-A1 | ANTIVIRAL PHARMACEUTICAL COMPOSITION AND USE THEREOF | ZC3HAV1, ZC3HAV1L, SARS1 | CSF1R 3618/4885CARM1 4063/4885PIK3CA 1322/4885 |
| US-20100197673-A1 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | IDO1, IDO2, NFATC1 | CSF1R 2910/4885CARM1 4637/4885PIK3CA 2096/4885 |
| US-20150038500-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING OPHTHALMIC DISORDERS | AQP1, EYA3, SF1 | CSF1R 3822/4885CARM1 3226/4885PIK3CA 2732/4885 |
| US-20240269145-A1 | USE OF INDOLE COMPOUND AS INHIBITORS OF FERROPTOSIS | AIFM2, FECH, SLC40A1 | CSF1R 1524/4885CARM1 2473/4885PIK3CA 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.